iwAL 2018 Session VI

 

Novel Approaches and Targeted Therapies in AML

Session VI at iwAL 2018 saw targeted therapies and novel approaches in AML discussed, with e-learning webinars from Jorge Cortes, MD, Andrew Wei, MBBS, PhD, FRACP, FRCPA, Mark Levis, MD, PhD, Jeffrey Lancet, MD, Stephane de Botton, MD, PhD, Martin Tallman, MD. Various therapies came into focus, including BCL-2 inhibitors, FLT3+ targets, IDH inhibitors, liposomal formations and a novel SMO inhibitor.

Presentations
SMO and Hedgehog Signalling – Glasdegib
Jorge Cortes, MD
University of Texas MD Anderson Cancer Center, Houston, TX
11 February, 2018

Jorge Cortes, MD, from the University of Texas MD Anderson Cancer Center, Houston, TX, talks about the novel SMO inhibitor glasdegib.

BCL-2 Inhibitors and Combinations – Venetoclax
Andrew Wei, MBBS, PhD, FRACP, FRCPA
Monash University, Victoria, Australia
11 February, 2018

Andrew Wei, MBBS, PhD, FRACP, FRCPA, from Monash University, Victoria, Australia, discusses using BCL-2 inhibitors as part of combination therapies.

New Therapies for FLT3+ AML – Midostaurin, Gilteritinib & Quizartinib
Mark Levis, MD, PhD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD
11 February, 2018

Mark Levis, MD, PhD, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, outlines the new therapies for FLT3+ AML.

Liposomal Advances (Daunorubicin & Cytarabine)
Jeffrey Lancet, MD
Moffitt Cancer Center, Tampa, FL
11 February, 2018

Jeffrey Lancet, MD, from the Moffitt Cancer Center, Tampa, FL, talks about exciting liposomal advances in AML.

IDH1 & IDH2 Inhibitors
Stephane de Botton, MD, PhD
Gustave Roussy Institute, Paris, France
11 February, 2018

Stephane de Botton, MD, PhD, from the Gustave Roussy Institute, Paris, France, discusses IDH1 and IDH2 inhibitors.

Incorporating Emerging Therapies into the Treatment of AML
Martin Tallman, MD
Memorial Sloan Kettering Cancer Center, New York, NY
11 February, 2018

Martin Tallman, MD, Memorial Sloan Kettering Cancer Center, New York, NY, presents on incorporating emerging therapies into the treatment of AML.